<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399281</url>
  </required_header>
  <id_info>
    <org_study_id>EU 260353</org_study_id>
    <nct_id>NCT01399281</nct_id>
  </id_info>
  <brief_title>Pharmacovigilance in Juvenile Idiopathic Arthritis Patients Treated With Biologic Agents and/or Methotrexate</brief_title>
  <acronym>PharmaChild</acronym>
  <official_title>Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (Pharmachild) Treated With Biologic Agents and/or Methotrexate. A PRINTO/PRES Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Giannina Gaslini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Members of the PRINTO network (PRINTO at www.printo.it)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Giannina Gaslini</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common chronic paediatric
      rheumatic disease (PRD) and an important cause of short and long-term disability. Although
      none of the available drugs for JIA has a curative potential, prognosis has greatly improved
      as a result of substantial progress in disease management. The therapeutic treatment of
      children with JIA encompasses the use of NSAIDs and intra-articular steroid injections. In
      those patients not responding to NSAIDs, methotrexate (MTX) has become the disease modifying
      anti-rheumatic drug (DMARD) of first choice worldwide. For children not responding to MTX,
      biologic agents recently have become treatment options.

      PATIENTS AND METHODS: 3-10 year observation study related to children with JIA undergoing
      treatment with MTX or biologic agents with the following objectives:

        1. To create a long-term observational registry of a large population of prevalent and
           incident cases.

        2. Use the accumulating data in the registry to conduct (i) a pharmacovigilance/safety
           study (primary endpoint) and (ii) estimate effectiveness (frequency and magnitude of
           response, disease activity over time inhibition or slowing of joint erosions and other
           radiological evidence of disease progression,), and (iii) estimate adherence to the
           various treatment regimens. Data from the registry will be used to compare safety and
           effectiveness profiles amongst the patient cohorts.

        3. To identify clinical and laboratory predictors of safety, response to therapy, including
           remission This project has retrospective (first 3 years) and prospective components (up
           to 10 years) and will be conducted by the participating centres of the more than 50
           countries belonging to the Paediatric Rheumatology INternational Trials Organisation
           (PRINTO certified ISO 9001-2008, www.printo.it), or the Pediatric Rheumatology European
           Society (PRES at www.pres.org.uk). The main role of these organisations is to provide a
           scientific basis for current treatments of paediatric rheumatic diseases.

      The overall hypothesis to be tested is:

      • Biologic agents ± MTX agents are able to maintain an acceptable safety profile in the long
      term in children with different JIA categories while achieving clinical remission and
      prevent/stop joint erosion development over time.

      The overall aims are to establish the long term safety of biologic agents and MTX, and their
      relative effectiveness in children with JIA who need treatment with second line agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is a 3-10 year, international, multicentre, observational, safety and
      efficacy (response, joint erosion, damage, and treatment adherence) study aimed at collecting
      prospective safety, tolerability, efficacy, and treatment adherence information on JIA
      subjects exposed to any biologic agents and MTX, according to local standard of practice.

      This is a non-interventional study, where the medicinal products are prescribed as per the
      investigator's decision. The assignment of the subject to a particular therapeutic strategy
      is not decided in advance by the study protocol, but falls within current practice and the
      prescription of the medicine is clearly separated from the decision to include the subject in
      the study. No additional diagnostic or monitoring procedures shall be applied to the subjects
      and epidemiological methods will be used for the analysis of collected data.

      Duration and treatment will be as per investigator's decision. The nature and frequency of
      subjects' visits to the investigator's site will be determined only by the investigator,
      according to his/her judgment on the basis of the clinical evolution of the subject.

      The duration of the study is expected to be at least 3 years from initiation of the first
      site and may be continued beyond if adequate funding is be available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>To compare the long term incidence rates of emergent moderate, severe adverse events (AEs) and serious A (SAE) observed in paediatric subjects with JIA. This will include but not be limited to, malignancies, opportunistic infections, autoimmune events, cardiovascular events, central nervous system involvement (e.g. optic neuritis, demyelinating disease), infertility, gastrointestinal bleeding, macrophage activation syndrome (MAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term efficacy in patients with JIA on biologics/MTX from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>To assess the long-term efficacy (magnitude of response, prevention or slowing of joint erosion and damage, and treatment adherence) of biologic agents and MTX for the treatment of children and adolescents with different categories of JIA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of safety from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>Identify predictors of safety (clinical or experimental, magnitude of response, remission)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factor from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>Assess potential risk factors (e.g. concomitant medications or diseases, medical history etc), which may modify the safety profile of biologic agents and MTX;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of children in treatment with biologics from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>To assess the number of children in which a biologic agent is added to the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wrist joint erosion from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>Evaluate the progression of wrist joint erosion over time and abnormal growth/maturation in JIA subjects presenting a wrist involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the reasons for stopping drug treatment from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>• To assess the reasons for stopping drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy from 3 to 10 years from drug initiation</measure>
    <time_frame>3-10 years</time_frame>
    <description>• To evaluate efficacy in terms, in the different JIA categories, of individual JIA core set variables, and the ACR Paediatric 30, 50, 70, 90, 100 criteria for improvement, and the achievement of clinical remission on and off medication as well as the occurrence of disease flare during biologic agents and MTX treatment course and after drug discontinuation, and the attainment of a status of minimal disease actvity (MDA)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Biologics alone or methotrexate alone</arm_group_label>
    <description>This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biologics and MTX</arm_group_label>
    <description>JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAIDs and/or steroid injections alone</arm_group_label>
    <description>This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female JIA patients selected among the PRINTO centres as part of the routine
        standard of care
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent by subjects and /or parent or legally acceptable
             representative;

          -  JIA (any ILAR category);

          -  Subjects receiving biologic agents ± MTX, MTX alone, or NSAIDs and/or steroid
             injections only as per physician discretion.

        Exclusion Criteria:

          -  Contraindications to biologic agents and/or MTX treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Ruperto, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto G. Gaslini/ PRINTO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PRINTO Member</last_name>
    <role>Study Director</role>
    <affiliation>All PRINTO members who will receive ethics committee approval</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Ruperto, MD, MPH</last_name>
    <phone>+39-010-382854</phone>
    <email>nicolaruperto@gaslini.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS G. Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicola Ruperto, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.printo.it</url>
    <description>Official website of the Paediatric Rheumatology International Trials Organisation (PRINTO)</description>
  </link>
  <reference>
    <citation>Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007 Mar 3;369(9563):767-78. Review.</citation>
    <PMID>17336654</PMID>
  </reference>
  <reference>
    <citation>Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med. 1992 Apr 16;326(16):1043-9.</citation>
    <PMID>1549149</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F, Vesely R, Foster H, Davidson J, Zulian F, Asplin L, Baildam E, Consuegra JG, Ozdogan H, Saurenmann R, Joos R, Pistorio A, Woo P, Martini A; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004 Jul;50(7):2191-201.</citation>
    <PMID>15248217</PMID>
  </reference>
  <reference>
    <citation>Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000 Mar 16;342(11):763-9.</citation>
    <PMID>10717011</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organisation; Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007 Sep;56(9):3096-106.</citation>
    <PMID>17763439</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008 Aug 2;372(9636):383-91. doi: 10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14.</citation>
    <PMID>18632147</PMID>
  </reference>
  <reference>
    <citation>Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20. doi: 10.1056/NEJMoa0706290.</citation>
    <PMID>18716298</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010 Jun;62(6):1792-802. doi: 10.1002/art.27431.</citation>
    <PMID>20191582</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, Xu S, Shen YK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010 Apr;69(4):718-22. doi: 10.1136/ard.2009.100354. Erratum in: Ann Rheum Dis. 2011 Nov;70(11):2060. Ann Rheum Dis. 2012 Jun;71(6):1106.</citation>
    <PMID>20237125</PMID>
  </reference>
  <reference>
    <citation>Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000 Aug;43(8):1849-57.</citation>
    <PMID>10943876</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, Kanakoudi-Tsakalidou F, Nielsen S, Bohnsack J, Gibbas D, Rennebohm R, Voygioyka O, Balogh Z, Lepore L, Macejkova E, Wulffraat N, Oliveira S, Russo R, Buoncompagni A, Hilário MO, Alpigiani MG, Passo M, Lovell DJ, Merino R, Martini A, Giannini EH; Pediatric Rheumatology Collaborative Study Group (PRCSG); Paediatric Rheumatology International Trials Organisation (PRINTO). Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006 Sep-Oct;24(5):599-605.</citation>
    <PMID>17181934</PMID>
  </reference>
  <reference>
    <citation>Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, Horneff G, Calvo I, Szer IS, Simpson K, Stewart JA, Strand V; Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005 Apr 21;352(16):1655-66.</citation>
    <PMID>15843668</PMID>
  </reference>
  <reference>
    <citation>van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Luijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998 May;41(5):808-16.</citation>
    <PMID>9588731</PMID>
  </reference>
  <reference>
    <citation>Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82. doi: 10.1002/acr.20460. Review.</citation>
    <PMID>21452260</PMID>
  </reference>
  <reference>
    <citation>Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997 Jul;40(7):1202-9.</citation>
    <PMID>9214419</PMID>
  </reference>
  <reference>
    <citation>Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004 Nov;31(11):2290-4.</citation>
    <PMID>15517647</PMID>
  </reference>
  <reference>
    <citation>Ruperto N, Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheumatol. 2011 Jan;7(1):6-7. doi: 10.1038/nrrheum.2010.199. Epub 2010 Dec 7.</citation>
    <PMID>21135880</PMID>
  </reference>
  <reference>
    <citation>Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010 Aug;62(8):2517-24. doi: 10.1002/art.27511.</citation>
    <PMID>20506368</PMID>
  </reference>
  <reference>
    <citation>Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010 Dec;62(12):3776-82. doi: 10.1002/art.27741.</citation>
    <PMID>20827782</PMID>
  </reference>
  <reference>
    <citation>Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009 May;68(5):648-53. doi: 10.1136/ard.2007.085852. Epub 2008 May 8.</citation>
    <PMID>18467516</PMID>
  </reference>
  <reference>
    <citation>Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.</citation>
    <PMID>19877027</PMID>
  </reference>
  <reference>
    <citation>Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.</citation>
    <PMID>19714630</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2011</study_first_submitted>
  <study_first_submitted_qc>July 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2011</study_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Giannina Gaslini</investigator_affiliation>
    <investigator_full_name>Dr. Nicola Ruperto</investigator_full_name>
    <investigator_title>MD, MPH</investigator_title>
  </responsible_party>
  <keyword>juvenile idiopathic arthritis, biologics, methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

